Management and long-term outcome of severe acute inflammatory bowel disease

被引:0
|
作者
Lehur, PA [1 ]
GuiberteauCanfrere, V [1 ]
LeBorgne, J [1 ]
机构
[1] HOP HOTEL DIEU,CLIN CHIRURG 2,F-44035 NANTES,FRANCE
来源
SEMAINE DES HOPITAUX | 1997年 / 73卷 / 13-14期
关键词
colitis; ulcerative; crohn disease; colonoscopy; colectomy; drug therapy;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Severe acute inflammatory bowel disease (SAIBD) poses several challenges to the clinician, who must recognize the severity of the flare, perform an accurate evaluation, and immediately select the most appropriate surgical and/or medical treatment. Once the diagnosis of inflammatory colitis is established, the severity of the flare should be assessed based on clinical and biochemical alterations that indirectly reflect the colonic involvement and, above all, on radiological and endoscopic visualization of the lesions. These investigations ensure identification of complications requiring emergency surgery (colonic perforation, colonic dilatation, severe bleeding). Patients without complications can be treated medically, under close supervision, with corticosteroid therapy (1 mg/kg/d), elimination of oral nutrition, and intravenous fluids and electrolytes. Surgery should be performed if this conservative approach fails; this is currently the most common situation in which surgery is performed in SAIBD. A third situation that requires surgery is occurrence of a relapse at discontinuation of the conservative treatment. Subtotal colectomy with ileostomy and sigmoidostomy is safe in emergency situations, ensures rapid recovery of a satisfactory general condition, supplies data of value for the etiologic diagnosis, and can be followed by any of the currently available techniques for restoring continuity: ileoanal anastomosis with reservoir (ulcerative colitis and indeterminate colitis) or ileorectal anastomosis (Crohn's disease) according to the condition of the rectum and anus, Iu the long-term, 80% of surgically-treated patients recover an unchanged body image and an acceptable to very satisfactory quality of life after an ileorectal or ileoanal anastomosis. Some patients, however, require a permanent ileostomy, particularly those with Crohn's disease diagnosed either during the acute episode or later, sometimes after an ileoanal anastomosis procedure.
引用
收藏
页码:409 / 416
页数:8
相关论文
共 50 条
  • [41] Incidentally Diagnosed Inflammatory Bowel Disease: Prevalence and Long-Term Outcomes
    Bronze, S. M. Tubal
    Shenoy, S.
    Agrawal, M.
    Colombel, J. F.
    Rodriguez-Lago, I
    Ungaro, R. C.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I802 - I802
  • [42] Safety of long-term mesalamine therapy in patients with inflammatory bowel disease
    Schroeder, KW
    Tremaine, WJ
    Albrecht, HH
    VerstBrasch, CL
    Zorich, NL
    GASTROENTEROLOGY, 1996, 110 (04) : A1011 - A1011
  • [43] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023, 22 (09) : 767 - 776
  • [44] The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease
    Robert N. Lopez
    Andrew S. Day
    Digestive Diseases and Sciences, 2021, 66 : 1390 - 1391
  • [45] Prevalence and long-term effect of antiplatelet use in inflammatory bowel disease
    Mantaka, A.
    Renieri, V.
    Koutroubakis, I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S249 - S250
  • [46] Long-term Clinical Experience with Vedolizumab in Patients with Inflammatory Bowel Disease
    Parikh, Asit
    Fox, Irving
    Leach, Timothy
    Xu, Jing
    Scholz, Catherine
    Patella, Michael
    Feagan, Brian G.
    INFLAMMATORY BOWEL DISEASES, 2013, 19 (08) : 1691 - 1699
  • [47] The Loneliness of Long-Term Thiopurine Monotherapy for Patients with Inflammatory Bowel Disease
    Lopez, Robert N.
    Day, Andrew S.
    DIGESTIVE DISEASES AND SCIENCES, 2021, 66 (05) : 1390 - 1391
  • [48] Severe inflammatory bowel disease: Medical management
    Farthing, MJG
    DIGESTIVE DISEASES, 2003, 21 (01) : 46 - 53
  • [49] FACTORS IN THE LONG-TERM PROGNOSIS OF PATIENTS WITH INFLAMMATORY BOWEL-DISEASE
    FARMER, RG
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 1981, 75 (02): : 97 - 103
  • [50] An update on the safety of long-term vedolizumab use in inflammatory bowel disease
    Honap, Sailish
    Netter, Patrick
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    EXPERT OPINION ON DRUG SAFETY, 2023,